

---

## **BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019**

CAMBRIDGE, Mass. and BEIJING, China, September 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in five poster presentations at the European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 – October 1, 2019 in Barcelona, Spain.

### **Poster Presentations:**

**Title: Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors**

Presentation #: 483P  
Date: Saturday, September 28  
Time: 12:00 – 13:00 CEST  
Location: Poster Area (Hall 4)  
Presenter: Chi-Yuan Wu, Ph.D., BeiGene

**Title: Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors**

Presentation #: 482P  
Date: Saturday, September 28  
Time: 12:00 – 13:00 CEST  
Location: Poster Area (Hall 4)  
Presenter: Chi-Yuan Wu, Ph.D., BeiGene

**Title: Updated Results of the PARP1/2 Inhibitor Pamiparib in Combination with Low-dose Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors**

Presentation #: 451PD  
Date: Saturday, September 28  
Time: 16:30 – 18:00 CEST



Location: Alicante Auditorium (Hall 3)  
Presenter: Agostina Stradella, M.D., Catalan Institute of Oncology, Spain

**Title: Safety, Antitumor Activity, and Pharmacokinetics of Pamiparib, a PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors: Updated Phase 1 Dose-Escalation/Expansion Results**

Presentation #: 452PD  
Date: Saturday, September 28  
Time: 16:30 – 18:00 CEST  
Location: Alicante Auditorium (Hall 3)  
Presenter: Mark Voskoboynik, MBBS, FRACP, Nucleus Network, Australia

**Title: First Report of Efficacy and Safety from a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma in Asian Patients**

Presentation #: 920P  
Date: Monday, September 30  
Time: 12:00 – 13:00 CEST  
Location: Poster Area (Hall 4)  
Presenter: Dingwei Ye, M.D., Ph.D., Fudan University Cancer Institute, China

## About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.<sup>1</sup>



BeiGene

BeiGene, Ltd.

---

**Investor Contact**

Craig West  
+1 857-302-5189  
ir@beigene.com

**Media Contact**

Liza Heapes  
+1 857-302-5663  
media@beigene.com

---

<sup>1</sup> ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.